Rankings
▼
Calendar
RXRX Q4 2020 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RXRX
Recursion Pharmaceuticals, Inc.
$2B
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$3M
100.0% margin
Operating Income
-$26M
-1002.8% margin
Net Income
-$26M
-1010.0% margin
EPS (Diluted)
$-0.15
QoQ Revenue Growth
+195.9%
Cash Flow
Operating Cash Flow
$9M
Free Cash Flow
$4M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$299M
Total Liabilities
$505M
Stockholders' Equity
-$206M
Cash & Equivalents
$262M
← FY 2020
All Quarters
Q1 2021 →
